Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi.

Pöhlmann, Johannes; Russel-Szymczyk, Monika; Holík, Pavel; Rychna, Karel; Hunt, Barnaby.

Afiliação

Pöhlmann J; Ossian Health Economics and Communications, Basel, Switzerland. poehlmann@ossianconsulting.com.
Russel-Szymczyk M; Novo Nordisk Pharma Sp. z.o.o., Warsaw, Poland.
Holík P; Novo Nordisk s.r.o., Prague, Czech Republic.
Rychna K; Novo Nordisk s.r.o., Prague, Czech Republic.
Hunt B; Ossian Health Economics and Communications, Basel, Switzerland.

Diabetes Ther ; 10(2): 493-508, 2019 Apr.

Article em En | MEDLINE | ID: mdl-30706364